Howard W. Robin
2021
In 2021, Howard W. Robin earned a total compensation of $11.2M as President and Chief Executive Officer at Nektar Therapeutics, a 1% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,000,350 |
|---|---|
| Option Awards | $3,326,492 |
| Salary | $1,053,000 |
| Stock Awards | $5,691,794 |
| Other | $81,980 |
| Total | $11,153,616 |
Robin received $5.7M in stock awards, accounting for 51% of the total pay in 2021.
Robin also received $1M in non-equity incentive plan, $3.3M in option awards, $1.1M in salary and $82K in other compensation.
Rankings
In 2021, Howard W. Robin's compensation ranked 870th out of 12,397 executives tracked by ExecPay. In other words, Robin earned more than 93.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 870 out of 12,397 | 93rd |
Division Manufacturing | 282 out of 5,492 | 95th |
Major group Chemicals And Allied Products | 94 out of 2,367 | 96th |
Industry group Drugs | 79 out of 2,090 | 96th |
Industry Pharmaceutical Preparations | 50 out of 1,537 | 97th |
Source: SEC filing on April 29, 2022.
Robin's colleagues
We found four more compensation records of executives who worked with Howard W. Robin at Nektar Therapeutics in 2021.
2021
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
2021
Jonathan Zalevsky
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
2021
John Northcott
Nektar Therapeutics
Senior Vice President and Chief Commercial Officer
2021
Mark Wilson
Nektar Therapeutics